Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: Final results of the DOGMES multicentre GINECO trial

Background: Metastatic breast cancer chemotherapy in the elderly is considered effective in carefully selected patients, but there is little data regarding its effect in vulnerable patients. Methods: We evaluated tumour response (primary endpoint), feasibility and outcomes after six courses of an adapted dose of pegylated liposomal doxorubicin (PLD) (40 mg/m 2 every 28 days) as first-line chemotherapy for hormone-resistant MBC. Results: Of 60 patients >70 years (median 77 years), 15% had performance status P2 and 73% had visceral metastases. Geriatric assessment included: P2 comorbidities, 42%; P1 deficiency in Activities of Daily Living (ADL), 10% and Instrumental ADL (IADL), 82%; living in